A BILL 
To provide for a demonstration project to further examine 
the benefits of providing coverage and payment for items 
and services necessary to administer intravenous immune 
globulin (IVIG) in the home, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medicare IVIG Access 
4
Enhancement Act’’. 
5
23:48 Jul 13, 2021
H3808
ctelli on DSK11ZRN23PROD with BILLS
2 
•HR 3808 IH
SEC. 2. MEDICARE PATIENT IVIG ACCESS DEMONSTRATION 
1
PROJECT. 
2
(a) ESTABLISHMENT.—The Secretary of Health and 
3
Human Services (in this section referred to as the ‘‘Sec-
4
retary’’) shall establish and implement a demonstration 
5
project under part B of title XVIII of the Social Security 
6
Act to evaluate the benefits of providing payment for items 
7
and services needed for the in-home administration of in-
8
travenous immune globulin for the treatment of chronic 
9
inflammatory demyelinating polyneuropathy or multifocal 
10
motor neuropathy. 
11
(b) DURATION AND SCOPE.— 
12
(1) DURATION.—Beginning not later than 1 
13
year after the date of enactment of this Act, the 
14
Secretary shall conduct the demonstration project 
15
for a period of 5 years. 
16
(2) SCOPE.—The Secretary shall, subject to 
17
subsection (d), enroll not greater than 3,000 Medi-
18
care beneficiaries who have been diagnosed with 
19
chronic inflammatory demyelinating polyneuropathy 
20
or multifocal motor neuropathy for participation in 
21
the demonstration project. Subject to subsection (d), 
22
a Medicare beneficiary may participate in the dem-
23
onstration project on a voluntary basis and may ter-
24
minate participation at any time. 
25
23:48 Jul 13, 2021
H3808
ctelli on DSK11ZRN23PROD with BILLS
3 
•HR 3808 IH
(c) COVERAGE.—Except as otherwise provided in this 
1
section, items and services for which payment may be 
2
made under the demonstration program shall be treated 
3
and covered under part B of title XVIII of the Social Se-
4
curity Act in the same manner as similar items and serv-
5
ices covered under such part. 
6
(d) ELIGIBILITY.—In order to participate in the dem-
7
onstration project, a Medicare beneficiary must— 
8
(1) be covered under the original Medicare fee- 
9
for-service program under parts A and B of title 
10
XVIII of the Social Security Act and not enrolled in 
11
a Medicare Advantage plan under part C of such 
12
Act; 
13
(2) require intravenous immunoglobulin for the 
14
treatment of chronic inflammatory demyelinating 
15
polyneuropathy or multifocal motor neuropathy; and 
16
(3) meet any other eligibility requirements spec-
17
ified by the Secretary. 
18
(e) PAYMENT.— 
19
(1) INTRAVENOUS IMMUNE GLOBULIN.—For in-
20
travenous immune globulin furnished under this sec-
21
tion, the Secretary shall make payment using the 
22
payment methodology under section 1847A of the 
23
Social Security Act (42 U.S.C. 1395w–3a). 
24
(2) OTHER ITEMS AND SERVICES.— 
25
23:48 Jul 13, 2021
H3808
ctelli on DSK11ZRN23PROD with BILLS
4 
•HR 3808 IH
(A) IN GENERAL.—The Secretary shall es-
1
tablish, subject to subparagraph (B), a per-visit 
2
payment amount for items and services (other 
3
than intravenous immune globulin) needed for 
4
the in-home infusion of intravenous immune 
5
globulin for the treatment of chronic inflam-
6
matory 
demyelinating 
polyneuropathy 
or 
7
multifocal motor neuropathy based on the na-
8
tional per visit low-utilization payment amount 
9
under the prospective payment system for home 
10
health services established under section 1895 
11
of the Social Security Act (42 U.S.C. 1395fff). 
12
(B) LIMITATION.—In establishing the per 
13
visit payment amount established under sub-
14
paragraph (A) for items and services described 
15
in such subparagraph, the Secretary shall con-
16
sider— 
17
(i) including a component for requisite 
18
nursing care; 
19
(ii) establishing an appropriate fur-
20
nishing fee for intravenous immune glob-
21
ulin similar to the separate payment for 
22
clotting factors under section 1842(o)(5) of 
23
the 
Social 
Security 
Act 
(42 
U.S.C. 
24
1395u(o)(5)); 
25
23:48 Jul 13, 2021
H3808
ctelli on DSK11ZRN23PROD with BILLS
5 
•HR 3808 IH
(iii) 
otherwise 
acknowledging 
the 
1
length of infusions for individuals needing 
2
in-home infusion of intravenous globulin 
3
for treatment described in subparagraph 
4
(A); 
5
(iv) that, in total, such amount poten-
6
tially not being less than at least 2.5 times 
7
the payment amount applied under the 
8
demonstration project established under 
9
section 101 of the Medicare IVIG Access 
10
and Strengthening Medicare and Repaying 
11
Taxpayers Act of 2012 (Public Law 112– 
12
242) for items and services needed for the 
13
in-home administration of intravenous im-
14
mune globulin for the treatment of pri-
15
mary immune deficiency diseases in rec-
16
ognition of the fact that patients with 
17
chronic inflammatory demyelinating poly-
18
neuropathy or multifocal motor neuropathy 
19
tend to have longer infusion times, require 
20
more product, and have additional health-
21
care needs related to underlying neuromus-
22
cular challenges; and 
23
(v) developing such amount in con-
24
sultation with stakeholders. 
25
23:48 Jul 13, 2021
H3808
ctelli on DSK11ZRN23PROD with BILLS
6 
•HR 3808 IH
(f) WAIVER AUTHORITY.—The Secretary may waive 
1
such requirements of title XVIII of the Social Security Act 
2
as may be necessary to carry out the demonstration 
3
project. 
4
(g) FINAL EVALUATION AND REPORT.—Not later 
5
than one year after the third year of the demonstration 
6
project, the Secretary shall submit to Congress a report 
7
that contains— 
8
(1) a current and projected evaluation of the 
9
impact of the demonstration project on access for 
10
Medicare beneficiaries with chronic inflammatory 
11
demyelinating polyneuropathy and Medicare bene-
12
ficiaries with multifocal motor neuropathy to items 
13
and services needed for the in-home administration 
14
of intravenous immune globin that also draws upon 
15
information and data from the ongoing home infu-
16
sion demonstration project for primary immuno-
17
deficiency diseases (Public Law 112–242) and the 
18
recent effort to provide an adequate coverage benefit 
19
for therapies infused through durable medical equip-
20
ment (HCPCS CMS–1738–P); and 
21
(2) a final analysis of the appropriateness of ex-
22
panding or extending the demonstration project, or 
23
implementing a new methodology for payment for in-
24
travenous immune globulins in all care settings 
25
23:48 Jul 13, 2021
H3808
ctelli on DSK11ZRN23PROD with BILLS
7 
•HR 3808 IH
under part B of title XVIII of the Social Security 
1
Act (42 U.S.C. 1395k et seq.), or augmenting exist-
2
ing benefits to provide proper access for home infu-
3
sion of intravenous immune globulins, and, to the 
4
extent such analysis determines such an expansion, 
5
extension, or methodology appropriate, recommenda-
6
tions for such expansion, extension, or methodology, 
7
respectively, along with an explanation of how CMS 
8
intends to implement or otherwise provide such a 
9
permanent benefit or mechanism for access during 
10
the fifth year of the demo to ensure nondisruptions 
11
in care for impacted patients. 
12
(h) DEFINITIONS.—In this section: 
13
(1) DEMONSTRATION
PROJECT.—The term 
14
‘‘demonstration project’’ means the demonstration 
15
project conducted under this Act. 
16
(2) 
MEDICARE
BENEFICIARY.—The 
term 
17
‘‘Medicare beneficiary’’ means an individual who is 
18
enrolled for benefits under part B of title XVIII of 
19
the Social Security Act. 
20
Æ 
23:48 Jul 13, 2021
H3808
ctelli on DSK11ZRN23PROD with BILLS
